Sepracor, Inc. engages in the research, discovery, development, and commercialization of pharmaceutical products for the treatment of respiratory and central nervous system disorders in the United States and Canada. It develops products for the synthesis and separation of pharmaceutical and biopharmaceutical compounds. The company markets XOPENEX (levalbuterol HCl) Inhalation Solution for the treatment of bronchospasm; XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane metered-dose inhaler for the treatment of bronchospasm; and LUNESTA (eszopiclone) for the treatment of insomnia. It also offers BROVANA (arformoterol tartrate) Inhalation Solution, a long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Sepracor’s out-licensing agreements include Schering-Plough for CLARINEX (desloratadine); sanofi-aventis for ALLEGRA (fexofenadine HCl); and UCB Pharma for XYZAL/XUSALTM (levocetirizine). It has other compounds in early stages of development for the treatment of central nervous system disorders, including Parkinson’s disease and depression. The company’s pipeline products comprise SEP-225289, under Phase I studies, is a serotonin, norepinephrine, and dopamine reuptake inhibitor for the treatment of major depressive disorder; SEP-227162, a serotonin and norepinephrine reuptake inhibitor for the treatment of depression and anxiety, is under Phase I clinical study; and SEP-226330 for central nervous system disorders, such as Parkinson’s disease. Sepracor offers its products to primary care physicians, allergists, pulmonologists, pediatricians, hospitals, psychiatrists, and sleep specialists through its sales professionals. It has an agreement with Eisai Co., Ltd. for the development and commercialization of its eszopiclone product, LUNESTA in Japan. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts.